ICU Medical (NASDAQ:ICUI) Insider Ben Sousa Sells 2,250 Shares

Posted by George Bondi on Aug 13th, 2026

ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the sale, the insider owned 3,076 shares in the company, valued at approximately $548,512.32. This trade represents a 42.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ICU Medical Stock Down 1.5%

ICUI stock opened at $179.34 on Thursday. The stock has a market capitalization of $4.48 billion, a P/E ratio of 151.98, a PEG ratio of 2.54 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical, Inc. has a one year low of $110.50 and a one year high of $192.85. The company has a 50 day moving average price of $154.67 and a two-hundred day moving average price of $141.46.

ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts expect that ICU Medical, Inc. will post 6.51 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the company. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Needham & Company LLC raised their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, BTIG Research upped their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Check Out Our Latest Analysis on ICUI

ICU Medical News Roundup

Here are the key news stories impacting ICU Medical this week:

Positive Sentiment: Strong earnings and margin expansion support the investment case. ICU Medical’s latest quarterly results exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million. A recent analysis also highlighted margin expansion and strength in the company’s infusion systems business. ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance
Positive Sentiment: Analysts raised price targets following the results. Needham lifted its target to $187, BTIG raised its target to $200, and Piper Sandler increased its target to $195 while maintaining an overweight rating. The consensus rating remains “Moderate Buy,” with an average price target of $192.80.
Neutral Sentiment: Institutional ownership remains high. Several smaller investment firms recently initiated or increased positions in ICU Medical, while institutional investors and hedge funds collectively own approximately 96.1% of the shares. The reported short-interest data showed zero shares short, offering little indication of short-selling pressure.
Negative Sentiment: Multiple insiders sold shares near recent highs. COO Christian B. Voigtlander sold 8,929 shares for approximately $1.63 million, CIO Ben Sousa sold 2,250 shares for about $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The sales reduced their respective holdings by approximately 19.3%, 42.3% and 7.2%, potentially raising investor concerns about insider conviction. Top ICU Medical Executive Makes a Notable Move With Company Stock

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of ICU Medical during the 2nd quarter worth about $550,250,000. Millennium Management LLC raised its holdings in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the period. Norges Bank purchased a new position in ICU Medical in the fourth quarter valued at approximately $58,083,000. Reinhart Partners LLC. purchased a new position in ICU Medical in the second quarter valued at approximately $46,148,000. Finally, Thrivent Financial for Lutherans lifted its position in ICU Medical by 1,604.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after buying an additional 285,648 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.